As a platform dedicated to comprehensive Antibody-Drug Conjugate (ADC) services, BOC Sciences has built a full-spectrum solution that spans early ADC discovery, drug construction, linker design, and in vivo pharmacological studies, supported by profound expertise in biochemistry and analytical technologies. Notably, BOC Sciences demonstrates strong technical capabilities and service capacity in the field of ADC drug distribution analysis. Drug distribution studies are a critical component in determining the pharmacokinetics (PK), tissue targeting, safety, and efficacy of ADCs. With its independently developed advanced analytical platform and diverse detection technologies, BOC Sciences is capable of accurately monitoring the distribution, release, and degradation of ADCs and their metabolites in vivo, providing scientific and systematic data support for drug development teams, and significantly accelerating the preclinical and clinical development of ADCs.
Drug distribution analysis can verify whether an ADC accurately localizes to the target tumor tissue and assess its ability to penetrate the tumor microenvironment. This is crucial for improving therapeutic efficiency and reducing side effects.
By studying the in vivo distribution of ADCs under different dosage conditions, drug distribution analysis provides scientific evidence for clinical trials and treatment, helping to avoid toxicity from overdosing or reduced efficacy from underdosing.
Drug distribution analysis is closely linked to pharmacokinetic parameters such as blood drug concentration and metabolite levels. It can further reveal the release mechanism and deconjugation behavior of ADCs, as well as their impact on therapeutic outcomes.
Distribution data can reveal whether ADCs accumulate in non-target tissues—particularly in organs like the liver and kidneys that are susceptible to drug toxicity—thereby aiding in the assessment of potential toxicological risks.
In the preclinical research and development of ADC drugs, drug distribution analysis is a core component that directly influences efficacy, safety, and translational success rates. Drawing on years of experience in antibody drug development, BOC Sciences has developed a systematic analytical service covering multiple dimensions such as plasma pharmacokinetics, tissue distribution, and toxin release. This service not only helps clients understand the in vivo dynamics of ADCs but also provides quantitative support for linker design, dose optimization, and toxicity prediction. Through standardized processes and a multi-technology integrated platform, BOC Sciences is committed to delivering precise and comprehensive data support for every ADC, accelerating its path from laboratory to clinic and market.
Utilizing high-sensitivity quantitative techniques such as LC-MS/MS and ELISA, BOC Sciences monitors the plasma concentrations of the intact ADC molecule, free toxins, and intermediate metabolites at various time points to construct accurate pharmacokinetic profiles and support dose design.
Through tissue quantitative analysis, the distribution ratios of ADCs in tumor tissue and major organs (liver, kidney, spleen, lung, etc.) are compared to evaluate targeting capability and off-target risks—an important parameter for assessing tumor enrichment capacity.
The amount and rate of toxin release due to linker cleavage are analyzed to verify the release efficiency of ADCs under target conditions. These data are vital for assessing linker stability and predicting toxicity.
By combining radiotracing or tissue imaging methods, it is determined whether toxin release is concentrated in tumor regions, whether it occurs in non-target tissues, and the specific time window of release, helping to optimize release strategies.
Using tissue sectioning, immunohistochemistry, and molecular imaging techniques, the spatial localization of ADC penetration depth and breadth in solid tumors is analyzed, enhancing understanding of and solutions for ADC treatment limitations.
To fully support the in vivo distribution research of ADC drugs, BOC Sciences has established an advanced and highly integrated drug distribution analysis platform that encompasses various high-sensitivity and high-resolution detection technologies. Centered on scientific rigor, the platform combines multidimensional methods such as radiolabeling, mass spectrometry quantification, immunohistochemical imaging, and molecular optical imaging to achieve accurate tracking and quantitative analysis of ADCs and their components in vivo. Whether evaluating antibody enrichment in tumors or analyzing toxin release and tissue penetration behaviors, the platform can provide high-quality, reproducible data to support ADC design optimization and safety assessment.
The company is equipped with internationally leading mass spectrometers (such as Triple Quad, Orbitrap), radioactive imaging devices, automated tissue sectioning and staining systems, and precision microscopic image analyzers, ensuring data accuracy and reproducibility.
We offer multi-mode labeling (radioactive/fluorescent/biotin, etc.) and toxin-specific site tracking, supporting independent monitoring and behavior analysis of different structural components within ADCs.
We provide comprehensive analysis services from exploratory research to preclinical development, offering project-specific technical support and flexibly adjusting analysis strategies based on client progress.
Utilizing PK/PD modeling, tissue drug distribution simulation, and ADC structure-activity relationship (SAR) analysis tools, we assist clients in efficacy prediction, dosage optimization, and toxicity evaluation.
The technical team communicates research goals with clients to determine analysis indicators, sampling time points, tissue types, and detection methods, and then formulates a customized research plan.
According to project needs, prepares radiolabeled/fluorescent/isotope-labeled ADCs or components, ensuring the activity and specificity of the analytes.
Administers the drug in models such as mice, rats, and monkeys, collects plasma, tumor, and major tissue samples at set time points, and performs cold chain transport and preservation.
Applies LC-MS/MS, IHC, molecular imaging, and other methods to process and analyze various samples, obtaining concentration and image data.
A professional data analysis team performs statistical modeling and result interpretation on raw data, generating detailed analysis reports and visualizations for client R&D decision-making.
Based on the analysis results, provides technical recommendations such as linker optimization, dosage adjustment, and tissue targeting strategy modification to support continuous project advancement and optimization.
Drug distribution refers to the process by which a drug, after entering the bloodstream, is transported and distributed among different tissues and organs in the body. It reflects the dynamic behavior of the drug moving from plasma to interstitial fluid and reaching concentration equilibrium in different organs. Drug distribution directly affects bioavailability, efficacy, and toxicity. Especially in targeted therapies such as ADCs, whether the drug can effectively accumulate in the target tissue is critical. The characteristics of drug distribution are influenced by the drug's physicochemical properties, physiological environment, and protein binding, making it one of the core contents in pharmacokinetic research.
Drug distribution is typically evaluated through in vivo pharmacokinetic experiments. The main methods include collecting plasma samples at different time points to plot plasma concentration–time curves and collecting animal tissue samples at specific time points to determine drug concentrations, thereby calculating tissue/plasma ratios (T/P ratios). In addition, techniques such as radiolabeling, LC-MS/MS, optical imaging, and immunohistochemistry can be used for quantitative tracking and tissue localization analysis. These methods allow researchers to clarify distribution trends, targeting ability, and off-target exposure risks, thereby optimizing drug design and administration strategies.
Drug distribution is influenced by multiple factors, mainly including:
Methods for studying drug distribution include various quantitative and imaging approaches:
These methods can be flexibly combined according to research needs to enhance the depth and reliability of distribution data.
